Completion of Divesture of Non-US Property

“The breadth of those knowledge displays our technique to advance numerous modalities for difficult-to-treat cancers,” mentioned Jay Bradner , M.D., government vp, Analysis and Improvement, and chief scientific officer at Amgen. “These ESMO outcomes underscore our management in oncology, contributing vital developments with each investigational and established therapies. Guided by a deep understanding of most cancers biology and leveraging incisive therapeutics, we are able to goal dominant drivers of illness with unprecedented precision.”

Key shows embody:

First findings from the Part 1b research of LUMAKRAS ^® plus Vectibix ^® together with FOLFIRI in first-line sufferers with KRAS G12C-mutated metastatic colorectal most cancers (mCRC).
Part 1 dose escalation and preliminary dose enlargement knowledge from AMG 193 chosen for a presidential symposium session.
First-in-human research of xaluritamig in males with metastatic castration-resistant prostate most cancers (mCRPC).

For extra data on the Amgen abstracts, see under.

Abstracts and Presentation Occasions:

Amgen Sponsored Abstracts

LUMAKRAS ^® (sotorasib) plus Vectibix ^® (panitumumab)

Sotorasib (soto) + panitumumab (pani) and FOLFIRI within the first line (1L) setting for KRAS-G12C mutated metastatic colorectal most cancers (mCRC): Security and efficacy from the part 1b CodeBreaK 101 research
Summary #505O, Proffered Paper Oral Session: 2, Madrid Auditorium – Corridor 2, Sunday, September 15 from 3: 05 – 3:15 p.m. CEST

AMG 193

Part 1 dose escalation and preliminary dose enlargement outcomes of AMG 193, an MTA-cooperative PRMT5 inhibitor, in sufferers (pts) with MTAP-deleted strong tumors
Summary #3482, Proffered Paper Oral Session: Presidential Symposium III: Eyes to the Future, Barcelona Auditorium – Corridor 2, Monday, September 16 from 16:30 – 18:15 p.m. CEST

Xaluritamig

C irculating tumor cell (CTC) enumeration and general survival (OS) in males with metastatic castration-resistant prostate most cancers (mCRPC) handled with xaluritamig
Summary #1610P, Poster, September 15
Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune remedy, in sufferers with metastatic castration-resistant prostate most cancers (mCRPC): Preliminary outcomes from dose enlargement cohorts in a Part 1 research
Summary #1598P, Poster, September 15

LUMAKRAS ^® (sotorasib) for NSCLC

Sotorasib long-term scientific outcomes in pre-treated KRAS G12C-mutated superior NSCLC: pooled evaluation from the CodeBreaK scientific trials
Summary #1305P, Poster, September 14
Medical traits and therapeutic sequences of KRAS G12C superior Non-Small Cell Lung Most cancers (aNSCLC) sufferers (pts) handled by sotorasib within the French post-marketing authorization early entry (post-MA EA)
Summary #1307P, Poster, September 14

Bemarituzumab

Fibroblast progress issue receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in sufferers with superior gastric or gastroesophageal junction most cancers (GC/GEJC)
Summary #1420P, Poster, September 16

Investigator Sponsored Research

Vectibix ^® (panitumumab)

**mRNA profiling as a biomarker of prognosis and response to first-line remedy in metastatic colorectal most cancers: discovery and validation of a gene expression signature in three randomized trials
Summary #581P, Poster, September 16
Circulating tumor DNA driving anti-EGFR rechallenge remedy in metastatic colorectal most cancers: the RASINTRO potential multicenter research
Summary #517P, Poster, September 16
Potential validation of the metastatic colon most cancers rating (mCCS) in sufferers with RAS wild-type metastatic colorectal most cancers handled with first-line panitumumab plus FOLFIRI/FOLFOX: Ultimate outcomes of the non-interventional research VALIDATE
Summary #585P, Poster, September 16

About LUMAKRAS ^® /LUMYKRAS ^® (sotorasib)
LUMAKRAS acquired accelerated approval from the U.S. Meals and Drug Administration (FDA) on Might 28, 2021 . The U.S. FDA accomplished its overview of Amgen’s supplemental New Drug Software (sNDA) looking for full approval of LUMAKRAS ^® on December 26, 2023 , which resulted in a whole response letter. As well as, the FDA concluded that the dose comparability postmarketing requirement (PMR) issued on the time of LUMAKRAS accelerated approval, to match the security and efficacy of LUMAKRAS 960 mg day by day dose versus a decrease day by day dose, has been fulfilled. 960 mg once-daily is the indicated dose for sufferers with KRAS G12C-mutated NSCLC underneath accelerated approval. The U.S. FDA additionally issued a brand new PMR for a further confirmatory research to help full approval that shall be accomplished no later than February 2028 .

About Metastatic Colorectal Most cancers and the KRAS G12C Mutation
Colorectal most cancers (CRC) is the second main reason for most cancers deaths worldwide, comprising 10% of all most cancers diagnoses. ¹ Additionally it is the third mostly identified most cancers globally. ²

KRAS mutations are among the many commonest genetic alterations in colorectal cancers, with the KRAS G12C mutation current in roughly 3-5% of colorectal cancers. ^3-5

About Superior Non-Small Cell Lung Most cancers and the KRAS G12C Mutation
Lung most cancers is the main reason for cancer-related deaths worldwide, and it accounts for extra deaths worldwide than colon most cancers, breast most cancers and prostate most cancers mixed. ⁶

KRAS G12C is the most typical KRAS mutation in NSCLC. ⁷ About 13% of sufferers with non-squamous NSCLC harbor the KRAS G12C mutation. ⁸

About CodeBreaK
The CodeBreaK scientific growth program for Amgen’s drug sotorasib is designed to check sufferers with a sophisticated strong tumor with the KRAS G12C mutation and handle the longstanding unmet medical want for these cancers.

Amgen additionally has a number of Part 1b research investigating sotorasib monotherapy and sotorasib mixture remedy throughout numerous superior strong tumors (CodeBreaK 101) open for enrollment. ⁹ A Part 2 randomized research evaluating sotorasib in sufferers with stage IV KRAS G12C-mutated NSCLC in want of first-line remedy is ongoing (CodeBreaK 201). ¹⁰ A Part 3 research of LUMAKRAS plus carboplatin and pemetrexed as front-line remedy in KRAS G12C-mutant, programmed death-ligand 1 (PD-L1) adverse superior NSCLC is enrolling sufferers (CodeBreaK 202). A Part 3 research of LUMAKRAS together with Vectibix and FOLFIRI in first-line KRAS G12C–mutated CRC can also be enrolling sufferers (CodeBreak-301).

LUMAKRAS ^® (sotorasib) U.S. Indication
LUMAKRAS is indicated for the remedy of grownup sufferers with KRAS G12C-mutated domestically superior or metastatic non-small cell lung most cancers (NSCLC), as decided by an FDA-approved take a look at, who have acquired at the least one prior systemic remedy.

This indication is authorized underneath accelerated approval primarily based on general response charge (ORR) and period of response (DOR). Continued approval for this indication could also be contingent upon verification and outline of scientific profit in a confirmatory trial(s).

LUMAKRAS ^® (sotorasib) Essential U.S. Security Info

Hepatotoxicity

LUMAKRAS could cause hepatotoxicity, which can result in drug-induced liver damage and hepatitis.
Amongst 357 sufferers who acquired LUMAKRAS in CodeBreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A complete of 18% of sufferers who acquired LUMAKRAS had elevated alanine aminotransferase (ALT)/elevated aspartate aminotransferase (AST); 6% had been Grade 3 and 0.6% had been Grade 4. Along with dose interruption or discount, 5% of sufferers acquired corticosteroids for the remedy of hepatotoxicity.
Monitor liver perform exams (ALT, AST and whole bilirubin) previous to the beginning of LUMAKRAS each 3 weeks for the primary 3 months of remedy, then as soon as a month or as clinically indicated, with extra frequent testing in sufferers who develop transaminase and/or bilirubin elevations.
Withhold, scale back or completely discontinue LUMAKRAS primarily based on severity of opposed response.

Interstitial Lung Illness (ILD)/Pneumonitis

LUMAKRAS could cause ILD/pneumonitis that may be deadly. Amongst 357 sufferers who acquired LUMAKRAS in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of sufferers, all instances had been Grade 3 or 4 at onset, and 1 case was deadly. LUMAKRAS was discontinued as a consequence of ILD/pneumonitis in 0.6% of sufferers.
Monitor sufferers for brand new or worsening pulmonary signs indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Instantly withhold LUMAKRAS in sufferers with suspected ILD/pneumonitis and completely discontinue LUMAKRAS if no different potential causes of ILD/pneumonitis are recognized.

Most Frequent Opposed Reactions

The commonest opposed reactions occurring in ≥ 20% had been diarrhea, musculoskeletal ache, nausea, fatigue, hepatotoxicity and cough.

Drug Interactions

Advise sufferers to tell their healthcare supplier of all concomitant medicines, together with prescription medicines, over-the-counter medicine, nutritional vitamins, dietary and natural merchandise.
Inform sufferers to keep away from proton pump inhibitors and H ₂ receptor antagonists whereas taking LUMAKRAS.
If coadministration with an acid-reducing agent can’t be averted, inform sufferers to take LUMAKRAS 4 hours earlier than or 10 hours after a domestically performing antacid.

Please see LUMAKRAS full Prescribing Info .

About Vectibix ^® (panitumumab)
Vectibix is the primary and solely absolutely human monoclonal anti-EGFR antibody authorized by the FDA for the remedy of mCRC. Vectibix was authorized within the U.S. in September 2006 as a monotherapy for the remedy of sufferers with EGFR-expressing mCRC after illness development after prior remedy with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

In Might 2014, the FDA authorized Vectibix to be used together with FOLFOX as first-line remedy in sufferers with wild-type KRAS (exon 2) mCRC. With this approval, Vectibix turned the first-and-only biologic remedy indicated to be used with FOLFOX, one of the generally used chemotherapy regimens, within the first-line remedy of mCRC for sufferers with wild-type KRAS mCRC.

In June 2017, the FDA authorized a refined indication for Vectibix to be used in sufferers with wild-type RAS (outlined as wild-type in each KRAS and NRAS as decided by an FDA-approved take a look at for this use) mCRC.

INDICATION AND LIMITATION OF USE

Vectibix ^® is indicated for the remedy of sufferers with wild-type RAS (outlined as wild-type in each KRAS and NRAS as decided by an FDA-approved take a look at for this use) metastatic colorectal most cancers (mCRC): as first-line remedy together with FOLFOX, and as monotherapy following illness development after prior remedy with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Limitation of Use: Vectibix ^® shouldn’t be indicated for the remedy of sufferers with RAS mutant mCRC or for whom RAS mutation standing is unknown.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: DERMATOLOGIC TOXICITY

Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of sufferers and had been extreme (NCI-CTC grade 3 and better) in 15% of sufferers receiving Vectibix monotherapy [see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].

In Research 20020408, dermatologic toxicities occurred in 90% of sufferers and had been extreme (NCI-CTC grade 3 and better) in 15% of sufferers with mCRC receiving Vectibix ^® . The scientific manifestations included, however weren’t restricted to, acneiform dermatitis, pruritus, erythema, rash, pores and skin exfoliation, paronychia, dry pores and skin, and pores and skin fissures.
Monitor sufferers who develop dermatologic or smooth tissue toxicities whereas receiving Vectibix ^® for the event of inflammatory or infectious sequelae. Life-threatening and deadly infectious issues together with necrotizing fasciitis, abscesses, and sepsis have been noticed in sufferers handled with Vectibix ^® . Life-threatening and deadly bullous mucocutaneous illness with blisters, erosions, and pores and skin sloughing has additionally been noticed in sufferers handled with Vectibix ^® . It couldn’t be decided whether or not these mucocutaneous opposed reactions had been straight associated to EGFR inhibition or to idiosyncratic immune- associated results (e.g., Stevens Johnson syndrome or poisonous epidermal necrolysis). Withhold or discontinue Vectibix ^® for dermatologic or smooth tissue toxicity related to extreme or life-threatening inflammatory or infectious issues. Dose modifications for Vectibix ^® regarding dermatologic toxicity are supplied within the product labeling.
Vectibix ^® shouldn’t be indicated for the remedy of sufferers with colorectal most cancers that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of both KRAS or NRAS and hereafter is known as ” RAS. ”
Retrospective subset analyses throughout a number of randomized scientific trials had been carried out to research the position of RAS mutations on the scientific results of anti-EGFR-directed monoclonal antibodies (panitumumab or cetuximab). Anti-EGFR antibodies in sufferers with tumors containing RAS mutations resulted in exposing these sufferers to anti-EGFR associated opposed reactions with out scientific profit from these brokers. Moreover, in Research 20050203, 272 sufferers with RAS -mutant mCRC tumors acquired Vectibix ^® together with FOLFOX and 276 sufferers acquired FOLFOX alone. In an exploratory subgroup evaluation , OS was shorter (HR = 1.21, 95% CI: 1.01-1.45) in sufferers with RAS -mutant mCRC who acquired Vectibix ^® and FOLFOX versus FOLFOX alone.
Progressively reducing serum magnesium ranges resulting in extreme (grade 3-4) hypomagnesemia occurred in as much as 7% (in Research 20080763) of sufferers throughout scientific trials. Monitor sufferers for hypomagnesemia and hypocalcemia previous to initiating Vectibix ^® remedy, periodically throughout Vectibix ^® remedy, and for as much as 8 weeks after the completion of remedy. Different electrolyte disturbances, together with hypokalemia, have additionally been noticed. Replete magnesium and different electrolytes as applicable.
In Research 20020408, 4% of sufferers skilled infusion reactions and 1% of sufferers skilled extreme infusion reactions (NCI-CTC grade 3-4). Infusion reactions, manifesting as fever, chills, dyspnea, bronchospasm, and hypotension, can happen following Vectibix ^® administration. Deadly infusion reactions occurred in postmarketing expertise. Terminate the infusion for extreme infusion reactions.
Extreme diarrhea and dehydration, resulting in acute renal failure and different issues, have been noticed in sufferers handled with Vectibix ^® together with chemotherapy.
Deadly and nonfatal instances of interstitial lung illness (ILD) (1%) and pulmonary fibrosis have been noticed in sufferers handled with Vectibix ^® . Pulmonary fibrosis occurred in lower than 1% (2/1467) of sufferers enrolled in scientific research of Vectibix ^® . Within the occasion of acute onset or worsening of pulmonary signs interrupt Vectibix ^® remedy. Discontinue Vectibix ^® remedy if ILD is confirmed.
In sufferers with a historical past of interstitial pneumonitis or pulmonary fibrosis, or proof of interstitial pneumonitis or pulmonary fibrosis, the advantages of remedy with Vectibix ^® versus the danger of pulmonary issues have to be rigorously thought-about.
Publicity to daylight can exacerbate dermatologic toxicity. Advise sufferers to put on sunscreen and hats and restrict solar publicity whereas receiving Vectibix ^® .
Keratitis and ulcerative keratitis, identified danger elements for corneal perforation, have been reported with Vectibix ^® use. Monitor for proof of keratitis or ulcerative keratitis. Interrupt or discontinue Vectibix ^® for acute or worsening keratitis.
In an interim evaluation of an open-label, multicenter, randomized scientific trial within the first-line setting in sufferers with mCRC, the addition of Vectibix ^® to the mix of bevacizumab and chemotherapy resulted in decreased OS and elevated incidence of NCI-CTC grade 3-5 (87% vs 72%) opposed reactions. NCI-CTC grade 3-4 opposed reactions occurring at the next charge in Vectibix ^® -treated sufferers included rash/acneiform dermatitis (26% vs 1%), diarrhea (23% vs 12%), dehydration (16% vs 5%), primarily occurring in sufferers with diarrhea, hypokalemia (10% vs 4%), stomatitis/mucositis (4% vs
NCI-CTC grade 3-5 pulmonary embolism occurred at the next charge in Vectibix ^® -treated sufferers (7% vs 3%) and included deadly occasions in three ( ® -treated sufferers. On account of the toxicities skilled, sufferers randomized to Vectibix ^® , bevacizumab, and chemotherapy acquired a decrease imply relative dose depth of every chemotherapeutic agent (oxaliplatin, irinotecan, bolus 5-FU, and/or infusional 5-FU) over the primary 24 weeks on research in contrast with these randomized to bevacizumab and chemotherapy.
Vectibix ^® could cause fetal hurt when administered to a pregnant girl. Advise pregnant girls and females of reproductive potential of the potential danger to a fetus. Advise females of reproductive potential to make use of efficient contraception throughout remedy, and for at the least 2 months after the final dose of Vectibix ^® .
In monotherapy, probably the most generally reported opposed reactions (≥ 20%) in sufferers with Vectibix ^® had been pores and skin rash with variable shows, paronychia, fatigue, nausea, and diarrhea.
Probably the most generally reported opposed reactions (≥ 20%) with Vectibix ^® + FOLFOX had been diarrhea, stomatitis, mucosal irritation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry pores and skin. The commonest critical opposed reactions (≥ 2% distinction between remedy arms) had been diarrhea and dehydration.

To see the Vectibix ^® Prescribing Info, together with Boxed Warning go to www.vectibix.com .

About Amgen
Amgen discovers, develops, manufactures and delivers revolutionary medicines to assist thousands and thousands of sufferers of their struggle in opposition to a number of the world’s hardest ailments. Greater than 40 years in the past, Amgen helped to ascertain the biotechnology trade and stays on the cutting-edge of innovation, utilizing expertise and human genetic knowledge to push past what’s identified as we speak. Amgen is advancing a broad and deep pipeline that builds on its current portfolio of medicines to deal with most cancers, coronary heart illness, osteoporosis, inflammatory ailments and uncommon ailments.

In 2024, Amgen was named one of many “World’s Most Modern Corporations” by Quick Firm and one among “America’s Greatest Giant Employers” by Forbes, amongst different exterior recognitions . Amgen is among the 30 corporations that comprise the Dow Jones Industrial Common ^® , and it’s also a part of the Nasdaq-100 Index ^® , which incorporates the biggest and most revolutionary non-financial corporations listed on the Nasdaq Inventory Market primarily based on market capitalization.

For extra data, go to Amgen.com and observe Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads .

Amgen Ahead-Wanting Statements
This information launch incorporates forward-looking statements which can be primarily based on the present expectations and beliefs of Amgen. All statements, aside from statements of historic truth, are statements that may very well be deemed forward-looking statements, together with any statements on the end result, advantages and synergies of collaborations, or potential collaborations, with every other firm (together with BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the efficiency of Otezla ^® (apremilast) (together with anticipated Otezla gross sales progress and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (together with the possible efficiency and outlook of Horizon’s enterprise, efficiency and alternatives, any potential strategic advantages, synergies or alternatives anticipated because of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related bills going ahead), in addition to estimates of revenues, working margins, capital expenditures, money, different monetary metrics, anticipated authorized, arbitration, political, regulatory or scientific outcomes or practices, buyer and prescriber patterns or practices, reimbursement actions and outcomes, results of pandemics or different widespread well being issues on our enterprise, outcomes, progress, and different such estimates and outcomes. Ahead-looking statements contain vital dangers and uncertainties, together with these mentioned under and extra absolutely described within the Securities and Change Fee experiences filed by Amgen, together with our most up-to-date annual report on Kind 10-Okay and any subsequent periodic experiences on Kind 10-Q and present experiences on Kind 8-Okay. Except in any other case famous, Amgen is offering this data as of the date of this information launch and doesn’t undertake any obligation to replace any forward-looking statements contained on this doc because of new data, future occasions or in any other case.

No forward-looking assertion will be assured and precise outcomes might differ materially from these we challenge. Discovery or identification of recent product candidates or growth of recent indications for current merchandise can’t be assured and motion from idea to product is unsure; consequently, there will be no assure that any specific product candidate or growth of a brand new indication for an current product shall be profitable and grow to be a industrial product. Additional, preclinical outcomes don’t assure protected and efficient efficiency of product candidates in people. The complexity of the human physique can’t be completely, or generally, even adequately modeled by laptop or cell tradition methods or animal fashions. The size of time that it takes for us to finish scientific trials and acquire regulatory approval for product advertising and marketing has previously different and we count on related variability sooner or later.

Even when scientific trials are profitable, regulatory authorities might query the sufficiency for approval of the trial endpoints we now have chosen. We develop product candidates internally and thru licensing collaborations, partnerships and joint ventures. Product candidates which can be derived from relationships could also be topic to disputes between the events or might show to be not as efficient or as protected as we might have believed on the time of getting into into such relationship. Additionally, we or others may establish security, negative effects or manufacturing issues with our merchandise, together with our gadgets, after they’re in the marketplace.

Our outcomes could also be affected by our capability to efficiently market each new and current merchandise domestically and internationally, scientific and regulatory developments involving present and future merchandise, gross sales progress of lately launched merchandise, competitors from different merchandise together with biosimilars, difficulties or delays in manufacturing our merchandise and international financial circumstances. As well as, gross sales of our merchandise are affected by pricing strain, political and public scrutiny and reimbursement insurance policies imposed by third-party payers, together with governments, non-public insurance coverage and managed care suppliers and could also be affected by regulatory, scientific and guideline developments and home and worldwide tendencies towards managed care and healthcare value containment. Moreover, our analysis, testing, pricing, advertising and marketing and different operations are topic to in depth regulation by home and international authorities regulatory authorities. Our enterprise could also be impacted by authorities investigations, litigation and product legal responsibility claims. As well as, our enterprise could also be impacted by the adoption of recent tax laws or publicity to further tax liabilities. If we fail to satisfy the compliance obligations within the company integrity settlement between us and the U.S. authorities, we may grow to be topic to vital sanctions. Additional, whereas we routinely acquire patents for our merchandise and expertise, the safety supplied by our patents and patent functions could also be challenged, invalidated or circumvented by our rivals, or we might fail to prevail in current and future mental property litigation. We carry out a considerable quantity of our industrial manufacturing actions at a number of key services, together with in Puerto Rico, and in addition rely upon third events for a portion of our manufacturing actions, and limits on provide might constrain gross sales of sure of our present merchandise and product candidate growth. An outbreak of illness or related public well being risk, akin to COVID-19, and the general public and governmental effort to mitigate in opposition to the unfold of such illness, may have a big opposed impact on the provision of supplies for our manufacturing actions, the distribution of our merchandise, the commercialization of our product candidates, and our scientific trial operations, and any such occasions might have a cloth opposed impact on our product growth, product gross sales, enterprise and outcomes of operations. We depend on collaborations with third events for the event of a few of our product candidates and for the commercialization and gross sales of a few of our industrial merchandise. As well as, we compete with different corporations with respect to lots of our marketed merchandise in addition to for the invention and growth of recent merchandise. Additional, some uncooked supplies, medical gadgets and part elements for our merchandise are provided by sole third-party suppliers. Sure of our distributors, clients and payers have substantial buying leverage of their dealings with us. The invention of great issues with a product just like one among our merchandise that implicate a whole class of merchandise may have a cloth opposed impact on gross sales of the affected merchandise and on our enterprise and outcomes of operations. Our efforts to collaborate with or purchase different corporations, merchandise or expertise, and to combine the operations of corporations or to help the merchandise or expertise we now have acquired, is probably not profitable. There will be no assure that we can understand any of the strategic advantages, synergies or alternatives arising from the Horizon acquisition, and such advantages, synergies or alternatives might take longer to comprehend than anticipated. We might not be capable of efficiently combine Horizon, and such integration might take longer, be harder or value greater than anticipated. A breakdown, cyberattack or data safety breach of our data expertise methods may compromise the confidentiality, integrity and availability of our methods and our knowledge. Our inventory worth is risky and could also be affected by various occasions. Our enterprise and operations could also be negatively affected by the failure, or perceived failure, of reaching our environmental, social and governance goals. The consequences of worldwide local weather change and associated pure disasters may negatively have an effect on our enterprise and operations. International financial circumstances might enlarge sure dangers that have an effect on our enterprise. Our enterprise efficiency may have an effect on or restrict the power of our Board of Administrators to declare a dividend or our capability to pay a dividend or repurchase our widespread inventory. We might not be capable of entry the capital and credit score markets on phrases which can be favorable to us, or in any respect.

The scientific data mentioned on this information launch associated to our product candidates is preliminary and investigative. Such product candidates should not authorized by the U.S. Meals and Drug Administration, and no conclusions can or must be drawn relating to the security or effectiveness of the product candidates. Additional, any scientific data mentioned on this information launch referring to new indications for our merchandise is preliminary and investigative and isn’t a part of the labeling authorized by the U.S. Meals and Drug Administration for the merchandise. The merchandise should not authorized for the investigational use(s) mentioned on this information launch, and no conclusions can or must be drawn relating to the security or effectiveness of the merchandise for these makes use of.

CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (buyers)

References

Rawla, P, et al. Gastroenterology Assessment. 2019;14(2):89-103.
World Well being Group. 2022 Statistics. Accessible at: https://www.who.int/en/news-room/fact-sheets/element/most cancers . Accessed on Might 17, 2024 .
Neumann J, et al. Frequency and kind of KRAS mutations in routine diagnostic evaluation of metastatic colorectal most cancers. Pathol Res Pract . 2009;205(12):858-862.
Jones RP, et al. Particular mutations in KRAS codon 12 are related to worse general survival in sufferers with superior and recurrent colorectal most cancers. Br J Most cancers . 2017;116(7):923-929.
Wiesweg M, et al. Affect of RAS mutation subtype on scientific outcome-a cross-entity comparability of sufferers with superior non-small cell lung most cancers and colorectal most cancers. Oncogene . 2019;38(16):2953-2966.
Sung H, et al. CA Most cancers J Clin. 2021;71:209-249.
Arbour KC, et al. Results of Co-occurring Genomic Alterations on Outcomes in Sufferers with KRAS- Mutant Non-Small Cell Lung Most cancers. Clin Most cancers Res . 2018;24:334-340.
Nassar AF, et al. Distribution of KRAS ^G12C Somatic Mutations throughout Race, Intercourse, and Most cancers Kind. N Engl J. Med . 2021;384:185-187.
ClinicalTrials.gov . CodeBreaK 101. Accessible at: https://clinicaltrials.gov/ct2/present/NCT04185883 . Accessed on Might 7, 2024 .
ClinicalTrials.gov . CodeBreaK 201. Accessible at: https://clinicaltrials.gov/ct2/present/NCT04933695 . Accessed on Might 7, 2024 .